145 related articles for article (PubMed ID: 19450094)
1. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
[TBL] [Abstract][Full Text] [Related]
2. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
5. Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Arellano J; Leteneux C
J Med Econ; 2008; 11(2):363-66; author reply 366-70. PubMed ID: 19450092
[No Abstract] [Full Text] [Related]
6. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Nadler E; Forsyth M; Satram-Hoang S; Reyes C
J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
[TBL] [Abstract][Full Text] [Related]
7. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
Bartminski W
Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Melosky B; Peacock S
J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
13. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
16. New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G
Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
Asukai Y; Valladares A; Camps C; Wood E; Taipale K; Arellano J; Cassinello A; Sacristán JA; Dilla T
BMC Cancer; 2010 Jan; 10():26. PubMed ID: 20113499
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
